Summary
Risk factor modification to prevent the development of coronary heart disease (CHD) is a rapidly growing concern of physicians interested in disease prevention. Drug treatments to reduce hypertension and hyperlipidaemia are 2 important interventions for CHD primary prevention. The benefits of these interventions have been demonstrated in short term clinical trials by reducing the incidence of stroke and coronary events. While the short term benefits may appear modest, the long term changes in life expectancy and disease morbidity may be substantial for carefully targeted groups of patients. Computer models are therefore increasingly being used to estimate the long term benefits of risk factor modification among selected patients. A review of published CHD models demonstrates that predictions among the different models are usually consistent. Moreover, the results of randomised clinical trials can be accurately forecasted using the CHD Primary Prevention Model.
Similar content being viewed by others
References
Abbott RD, McGee D. The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics. Section 37. In Kannel et al. (Eds) The Framingham Study: an epidemiological investigation of cardiovascular disease, US Department of Health, Education, and Welfare publication NIH 87-2284, US Government Printing Office, Bethesda, 1987
American Cancer Society. ACS report on the cancer-related checkup. A Cancer Journal for Clinicians 30: 194–240, 1980
American College of Physicians, Medical Practice Committee. Periodic health examinations: a guide for designing individualized preventive health care in the asymptomatic patient. Annals of Internal Medicine 95: 729–732, 1981
American Heart Association, Nutrition Committee. A statement for physicians and health professionals by the Nutrition Committee, American Heart Association. Dietary guidelines for healthy American adults. Circulation 77: 721A-724A, 1989
Canadian Consensus Conference on Cholesterol: final report. Canadian Medical Association Journal 139 (Suppl.): 1–8, 1988
Canadian Task Force on the Periodic Health Examination. The periodic health examination. Canadian Medical Association Journal 121: 1193–1254, 1979
Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, et al. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension. (STOP —Hypertension). Lancet 338: 1281–1285, 1991
Frick MH, Elo O, Haapa K, Heinohen OP, Heinsalmi P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middleaged men with dyslipidemia. New England Journal of Medicine 317: 1237–1245, 1987
Grover SA, Abrahamowicz M, Joseph L, Brewer C, Coupai L, et al. The benefits of treating hyperlipidemia to prevent coronary heart disease. Journal of the American Medical Association 267: 816–822, 1992
Grover SA, Gray-Donald K, Joseph L, Abrahamowicz M, Coupai L. Life expectancy following dietary modification or smoking cessation: estimating the benefits of a prudent lifestyle. Archives of Internal Medicine, in press, 1994
Kannel WB, Wolf PA, Garrison RJ. The Framingham Study, section 35: survival following initial cardiovascular events. Thirty year follow-up. National Heart, Lung, and Blood Institute Publication, NIH 88-2969, US Government Printing Office, Bethesda, 1988
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in the incidence of coronary heart disease. Journal of the American Medical Association 251: 351–364, 1984
Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal 291: 97–104, 1985
Muldoon MF, Manuck SB, Matthews HA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. British Medical Journal 301: 309–314, 1990
Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. Journal of the American Medical Association 248: 1465–1477, 1982
Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial: findings related to a priori hypothesis of the trial. Journal of the American Medical Association 263: 1795–1801, 1990
National Cholesterol Education Program. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Archives of Internal Medicine 148: 36–69, 1988
Oster G, Huse DM, Delea TE, Colditz GA. Cost effectiveness of nicotine gum as an adjunct to physician’s advice against cigarette smoking. Journal of the American Medical Association 256:1315–1318, 1986
Oster G, Epstein AM. Cost effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease. The case of cholestyramine. Journal of the American Medical Association 258: 2381–2387, 1987
Shurtleff D. Some characteristics related to the incidence of cardiovascular disease and death: Framingham Study, 18 year follow-up. Section 30. In Kannel & Gordon (Eds) The Framingham Study: an epidemiological investigation of cardiovascular disease. US Department of Health, Education, and Welfare Publication, NIH 74-599, US Government Printing Office, Bethesda, 1974
Statistics Canada, Health Division. Vital statistics and disease registries section. (Formerly Catalogue 84-532). Life tables, Canada and provinces, 1985–1987, Statistics Canada, Ottawa, 1989
Taylor WC, Pass TM, Sheperd DS, Komaroff AL. Cholesterol reduction and life expectancy. A model incorporating multiple risk factors. Annals of Internal Medicine 106: 605–614, 1987
Tsevat J, Weinstein MC, Williams LS, Tosteson ANA, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 83: 1194–1201, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grover, S.A., Coupal, L. Risk-Benefit Assessment of Drug Treatment to Prevent Coronary Heart Disease Estimating the Benefits of Risk Factor Modification. Drug-Safety 10, 301–309 (1994). https://doi.org/10.2165/00002018-199410040-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199410040-00004